Autoregulation of TDP-43 mRNA levels involves interplay between transcription, splicing, and alternative polyA site selection

Genes and Development

Volumn 26, Issue 15, 2012, Pages 1679-1684

  Erendira Avendano Vazquez S ^a   Dhir, Ashish ^b   Bembich, Sara ^a   Buratti, Emanuele ^a   Proudfoot, Nicholas ^b   Baralle, Francisco E ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

ALS; Autoregulation; FTD; mRNA splicing; Poly adenylation; TDP 43

Indexed keywords

ANTIBODY; MESSENGER RNA;

3' UNTRANSLATED REGION; ALTERNATIVE RNA SPLICING; ANIMAL TISSUE; ARTICLE; AUTOREGULATION; COMPLEX FORMATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; INTRON; MOLECULAR RECOGNITION; MOUSE; NEUROPATHOLOGY; NONHUMAN; POLYADENYLATION; PRIORITY JOURNAL; PROTEIN BINDING; RNA SPLICING; RNA TRANSCRIPTION; TDP 43 PROTEINOPATHY;

ALTERNATIVE SPLICING; ANIMALS; BASE SEQUENCE; CELL LINE; CLEAVAGE STIMULATION FACTOR; DNA-BINDING PROTEINS; HOMEOSTASIS; HUMANS; INTRONS; MICE; MOLECULAR SEQUENCE DATA; POLY A; PROTEIN BINDING; RNA SPLICE SITES; RNA SPLICING; RNA, MESSENGER; RNA-BINDING PROTEINS; TRANSCRIPTION, GENETIC;

MAMMALIA; MUS;

EID: 84864762305     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.194829.112     Document Type: Article

References (35)

1. Ayala YM, Zago P, D'Ambrogio A, Xu YF, Petrucelli L, Buratti E, Baralle FE. 2008. Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci 121: 3778-3785.
2. Ayala YM, De Conti L, Avendano-Vazquez SE, Dhir A, Romano M, D'Ambrogio A, Tollervey J, Ule J, Baralle M, Buratti E, et al. 2011. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J 30: 277-288.
3. Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S. 2010. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J Neurosci 30: 639-649.
4. Buratti E, Baralle FE. 2001. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem 276: 36337-36343.
5. Buratti E, Baralle FE. 2011. TDP-43: New aspects of autoregulation mechanisms in RNA binding proteins and their connection with human disease. FEBS J 278: 3530-3538.
6. Chen-Plotkin AS, Geser F, Plotkin JB, Clark CM, Kwong LK, Yuan W, Grossman M, Van Deerlin VM, Trojanowski JQ, Lee VM. 2008. Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration. Hum Mol Genet 17: 1349-1362.
7. Dai W, Zhang G, Makeyev EV. 2012. RNA-binding protein HuR auto-regulates its expression by promoting alternative polyadenylation site usage. Nucleic Acids Res 40: 787-800.
8. Dye MJ, Proudfoot NJ. 1999. Terminal exon definition occurs cotranscrip-tionally and promotes termination of RNA polymerase II. Mol Cell 3: 371-378.
9. Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA. 2007. A chromatin landmark and transcription initiation at most promoters in human cells. Cell 130: 77-88.
10. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, Bouchard JP, Lacomblez L, Pochigaeva K, Salachas F, et al. 2008. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 40: 572-574.
11. Kaida D, Berg MG, Younis I, Kasim M, Singh LN, Wan L, Dreyfuss G. 2010. U1 snRNP protects pre-mRNAs from premature cleavage and polyadenylation. Nature 468: 664-668.
12. Kornblihtt AR. 2007. Coupling transcription and alternative splicing. Adv Exp Med Biol 623: 175-189.
13. Lareau LF, Brooks AN, Soergel DA, Meng Q, Brenner SE. 2007a. The coupling of alternative splicing and nonsense-mediated mRNA decay. Adv Exp Med Biol 623: 190-211.
14. Lareau LF, Inada M, Green RE, Wengrod JC, Brenner SE. 2007b. Unproductive splicing of SR genes associated with highly conserved and ultraconserved DNA elements. Nature 446: 926-929.
15. Lejeune F, Maquat LE. 2005. Mechanistic links between nonsense-mediated mRNA decay and pre-mRNA splicing in mammalian cells. Curr Opin Cell Biol 17: 309-315.
16. Li Y, Ray P, Rao EJ, Shi C, Guo W, Chen X, Woodruff EA III, Fushimi K, Wu JY. 2010. A Drosophila model for TDP-43 proteinopathy. Proc Natl Acad Sci 107: 3169-3174.
17. Liachko NF, Guthrie CR, Kraemer BC. 2010. Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 protein-opathy. J Neurosci 30: 16208-16219.
18. Lutz CS, Moreira A. 2011. Alternative mRNA polyadenylation in eukaryotes: An effective regulator of gene expression. WIREs RNA 2: 22-31.
19. Mishra M, Paunesku T, Woloschak GE, Siddique T, Zhu LJ, Lin S, Greco K, Bigio EH. 2007. Gene expression analysis of frontotemporal lobar degeneration of the motor neuron disease type with ubiquitinated inclusions. Acta Neuropathol 114: 81-94.
20. Moore MJ, Proudfoot NJ. 2009. Pre-mRNA processing reaches back to transcription and ahead to translation. Cell 136: 688-700.
21. Ni JZ, Grate L, Donohue JP, Preston C, Nobida N, O'Brien G, Shiue L, Clark TA, Blume JE, Ares M Jr. 2007. Ultraconserved elements are associated with homeostatic control of splicing regulators by alternative splicing and nonsense-mediated decay. Genes Dev 21: 708-718.
22. Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling SC, Sun E, Wancewicz E, Mazur C, et al. 2011. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 14: 459-468.
23. Proudfoot NJ. 2011. Ending the message: Poly(A) signals then and now. Genes Dev 25: 1770-1782.
24. Rigo F, Martinson HG. 2009. Polyadenylation releases mRNA from RNA polymerase II in a process that is licensed by splicing. RNA 15: 823-836.
25. Saltzman AL, Kim YK, Pan Q, Fagnani MM, Maquat LE, Blencowe BJ. 2008. Regulation of multiple core spliceosomal proteins by alternative splicing-coupled nonsense-mediated mRNA decay. Mol Cell Biol 28: 4320-4330.
26. Skourti-Stathaki K, Proudfoot NJ, Gromak N. 2011. Human senataxin resolves RNA/DNA hybrids formed at transcriptional pause sites to promote Xrn2-dependent termination. Mol Cell 42: 794-805.
27. Takagaki Y, Manley JL. 1997. RNA recognition by the human poly-adenylation factor CstF. Mol Cell Biol 17: 3907-3914.
28. Takagaki Y, Manley JL. 1998. Levels of polyadenylation factor CstF-64 control IgM heavy chain mRNA accumulation and other events associated with B cell differentiation. Mol Cell 2: 761-771.
29. Tatom JB, Wang DB, Dayton RD, Skalli O, Hutton ML, Dickson DW, Klein RL. 2009. Mimicking aspects of frontotemporal lobar degeneration and Lou Gehrig's disease in rats via TDP-43 overexpression. Mol Ther 17: 607-613.
30. Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, Konig J, Hortobagyi T, Nishimura AL, Zupunski V, et al. 2011. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci 14: 452-458.
31. Wegorzewska I, Baloh RH. 2011. TDP-43-based animal models of neuro-degeneration: New insights into ALS pathology and pathophysiology. Neurodegener Dis 8: 262-274.
32. Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. 2009. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci 106: 18809-18814.
33. Weihl CC, Temiz P, Miller SE, Watts G, Smith C, Forman M, Hanson PI, Kimonis V, Pestronk A. 2008. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatr 79: 1186-1189.
34. Wils H, Kleinberger G, Janssens J, Pereson S, Joris G, Cuijt I, Smits V, Ceuterick-de Groote C, Van Broeckhoven C, Kumar-Singh S. 2010. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci 107: 3858-3863.
35. Xu YF, Gendron TF, Zhang YJ, Lin WL, D'Alton S, Sheng H, Casey MC, Tong J, Knight J, Yu X, et al. 2010. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci 30: 10851-10859.